This conference aims to take an international multi-stakeholder approach to discussing stem cell translational barriers and to assist in defining a blueprint for stem cell innovation, translation and commercialisation for spinal cord injury and related degenerative disorders of the central nervous system.

Who should attend? Academic and industry researchers, clinicians, health regulators, public policy officials, bio-ethicists, government, non-governmental organizations, consumers, and patient advocacy groups, business development officers and technology transfer officers, legal representatives